Actis acquires cancer and spacer technologies from US firms
This article was originally published in Scrip
Executive Summary
Actis Biologics, the Mumbai-based biotech research and technology incubator, has bought diverse patented technologies from the US firms CellPoint Diagnostics and CFD Research Corporation. Actis has acquired CellPoint's technology platform for the treatment of hepatic cancer and CFD's spacer technology for metered-dose inhalers.